Dovramilast

N/A

Report date: 2025/09/16 20:00:07
NME

Base Information

Drug NameDovramilast
Drug Alias NameCC-11050AMG-634
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsPhosphodieterase 4 inhibitors
TargetsTumor necrosis factor αPhosphodieterase 4
Therapy Area/IndicationsLupus Erythematosus, CutaneousHIV InfectionsTuberculosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBeninUnited StatesPhilippines +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesMedicines Development For Global Health Ltd
Inactive CompaniesAmgen IncNational Institute Of Allergy And Infectious Diseases (Niaid)The Aurum Institute
Active IndicationsLeprosy
Inactive IndicationsLupus Erythematosus, CutaneousHIV InfectionsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A